These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 18305454)

  • 41. Can underpowered clinical trials be justified?
    Rosoff PM
    IRB; 2004; 26(3):16-9. PubMed ID: 15281196
    [No Abstract]   [Full Text] [Related]  

  • 42. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and oversight of ethical health promotion quality assurance and evaluation activities involving human participants.
    Sainsbury P
    Health Promot J Austr; 2015 Dec; 26(3):176-181. PubMed ID: 26536392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accusations of bias prompt NIH review of ethical guidelines.
    Knight J
    Nature; 2003 Dec; 426(6968):741. PubMed ID: 14685178
    [No Abstract]   [Full Text] [Related]  

  • 45. Introduction to special issue of Accountability in Research on the review and approval of biomedical research proposals: a call for a centralized national human research protections system.
    Mann H; Shamoo AE
    Account Res; 2006; 13(1):1-9. PubMed ID: 16770856
    [No Abstract]   [Full Text] [Related]  

  • 46. Co-ordinating 'ethical' clinical trials: the role of research coordinators in the contract research industry.
    Fisher JA
    Sociol Health Illn; 2006 Sep; 28(6):678-94. PubMed ID: 17184412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reporting clinical trials: full access to all the data.
    Rosenberg RN; Aminoff M; Boller F; Soelberg P; Griggs RC; Hachinski V; Hallett M; Johnson RT; Kennard C; Lang AE; Lees AJ; Lisak R; Newsom-Davis J; Pedley TA; Selzer ME; Zochodne D
    Stroke; 2001 Dec; 32(12):2734. PubMed ID: 11739964
    [No Abstract]   [Full Text] [Related]  

  • 48. Views of the process and content of ethical reviews of HIV vaccine trials among members of US institutional review boards and South African research ethics committees.
    Klitzman R
    Dev World Bioeth; 2008 Dec; 8(3):207-18. PubMed ID: 19046258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ethical considerations in studying drug safety--the Institute of Medicine report.
    Mello MM; Goodman SN; Faden RR
    N Engl J Med; 2012 Sep; 367(10):959-64. PubMed ID: 22913661
    [No Abstract]   [Full Text] [Related]  

  • 50. Protection of research subjects.
    Pesando JM
    N Engl J Med; 2003 Jul; 349(2):188-92; author reply 188-92. PubMed ID: 12856655
    [No Abstract]   [Full Text] [Related]  

  • 51. Pragmatism as a complementary approach to legislation: closing regulatory gaps in human subject research.
    Vernillo A
    Am J Bioeth; 2008 Nov; 8(11):15-7. PubMed ID: 19061099
    [No Abstract]   [Full Text] [Related]  

  • 52. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal.
    Crépin S; Villeneuve C; Merle L
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):719-24. PubMed ID: 26887649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Call for a new approach to the process of clinical trials and drug registration.
    Jones TC
    BMJ; 2001 Apr; 322(7291):920-3. PubMed ID: 11302912
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical research projects at a German medical faculty: follow-up from ethical approval to publication and citation by others.
    Blümle A; Antes G; Schumacher M; Just H; von Elm E
    J Med Ethics; 2008 Sep; 34(9):e20. PubMed ID: 18757621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conflicts of interest at the NIH: no easy solution.
    Resnik DB
    Hastings Cent Rep; 2005; 35(1):18-20. PubMed ID: 15799496
    [No Abstract]   [Full Text] [Related]  

  • 57. Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns.
    Hughes S; Cohen D; Johnson R
    Int J Risk Saf Med; 2016 Aug; 28(2):101-14. PubMed ID: 27567767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.
    Lantos JD; Wendler D; Septimus E; Wahba S; Madigan R; Bliss G
    Clin Trials; 2015 Oct; 12(5):485-93. PubMed ID: 26374686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research ethics committees; good clinical practice; advance directives.
    Bull Med Ethics; 2005; (209):8-11. PubMed ID: 16830431
    [No Abstract]   [Full Text] [Related]  

  • 60. The use of placebos in clinical trials: responsible research or unethical practice?
    Hoffman S
    Conn Law Rev; 2001; 33(2):449-501. PubMed ID: 15732201
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.